503A vs 503B pharmacies: what's the difference?
Two kinds of compounding pharmacy, two different rule books, two different regulators — and neither one makes an FDA-approved drug. Here's what actually separates them, and what to ask the one filling your prescription.
Last reviewed July 14, 2026 · Sources cited and dated · Not legal or medical advice
Why this is worth four minutes
If you're taking a compounded medication, one of these two pharmacy types made it. They operate under different laws, answer to different regulators, and are allowed to use different ingredients under different conditions.
Almost nobody selling you a compounded drug explains which one they use, or why. That's not an accident — the distinction is where most of the real answers live.
The two types
503A and 503B are not two tiers of the same thing
They're two different legal creatures. The numbers refer to sections of the Federal Food, Drug, and Cosmetic Act.
| Attribute | 503ATraditional compounding pharmacy | 503BOutsourcing facility |
|---|---|---|
| Who they are | State-licensed pharmacy or physician | FDA-registered outsourcing facility |
| Regulated by | Primarily your state board of pharmacy | Primarily the FDA |
| Needs a prescription? | Yes — patient-specific. Compounded for one named individual | Not necessarily. Can produce batches for office use |
| Scale | Prescription by prescription | Larger batches |
| cGMP required? | No | Yes — current Good Manufacturing Practice |
| Which ingredients? | Must meet one of three conditions (below) | Must meet one of two conditions (below) |
| FDA-approved product? | No | No |
The row people misread is the last one. 503B facilities follow manufacturing standards that 503A pharmacies don't, and they're FDA-registered and inspected. That is a real difference and it is worth knowing. It is not approval.
An FDA-registered facility making a non-FDA-approved drug is exactly what it sounds like: the facility is registered, the drug isn't reviewed for safety, effectiveness, or manufacturing the way an approved drug is.
The rule sets
Each type gets a different set of doors
This is the part that decides what you can actually get, and it's why "my pharmacy says it's fine" isn't an answer on its own.
503A · three doors
A 503A pharmacy can use a bulk substance if any one of these is true
- it complies with a USP or NF monograph, if one exists; or
- if no monograph exists, it's a component of an FDA-approved drug product; or
- if neither applies, it appears on the 503A Bulks List.
503B · two doors
A 503B outsourcing facility can use a bulk substance if either is true
- it appears on the 503B Bulks List — substances FDA has determined there's a clinical need for; or
- it appears on FDA's drug shortage list at the time of compounding, distribution and dispensing.
Both types must also use substances with a valid certificate of analysis, made by an establishment registered with FDA.
One door is enough. Zero doors means no compliant pathway, whatever anyone tells you.
The three-door test, worked through for any compound → /are-peptides-legal
What Category 1, 2 and 3 actually mean → /fda-peptide-categories
The gap
A pharmacy can follow its state's rules and still be offside federally
503A pharmacies answer primarily to state boards of pharmacy. 503B facilities answer primarily to the FDA. Those two authorities do not always say the same thing at the same time.
The practical consequence: "we're a licensed pharmacy in good standing" is a true statement that answers a different question than the one you asked. State licensure is real, and it is not a federal compliance claim.
States including California, Michigan and New York have issued their own compounding guidance that sits on top of the federal floor. Whether a given product is lawful for you can depend on where you live — which is also why legitimate providers can't ship everything everywhere.
The mechanism, in real life
Watch a door close
The clearest illustration of all of this happened over the last two years, in public, with dates.
The door that was open
Both 503A and 503B are barred from compounding a drug that is "essentially a copy" of a commercially available FDA-approved drug. The exception: when the approved drug is on FDA's shortage list, it isn't considered commercially available. Semaglutide went on the shortage list in 2022 when demand outran supply. That flipped the switch, and compounded GLP-1s became lawful.
The door closing
On February 21, 2025, FDA declared the semaglutide shortage resolved. The shortage condition was the whole basis, so it went with it. FDA set wind-down dates: April 22, 2025 for 503A pharmacies, May 22, 2025 for 503B facilities.
The challenge
The Outsourcing Facilities Association sued. On April 24, 2025, the district court denied its preliminary injunction motion. The deadlines held.
The door being sealed
On April 30, 2026, FDA proposed to formally exclude semaglutide, tirzepatide and liraglutide from the 503B Bulks List — the clinical-need list. The comment period closed June 30, 2026, with over 4,200 comments filed. (Federal Register doc 2026-08552.)
What's left
503A patient-specific compounding remains lawful where a documented clinical need exists that the approved product can't meet — a documented allergy to an inactive ingredient, or a dose strength that isn't commercially available. Not "regularly or in inordinate amounts."
The part worth underlining
FDA has said affordability and insurance access do not constitute clinical need. Cost is the reason most people want a compounded version. It is not a reason the law recognizes.
None of that was a new law. It was a conditional permission expiring on schedule. That's the thing to understand about compounding generally: much of it runs on conditions, and conditions end.
The method
Five questions, and where to check the answers
- Which type is filling my prescription — 503A or 503B? A legitimate provider will name the pharmacy. Not "our pharmacy network." The name.
- If 503B: are they on FDA's registered outsourcing facility list? FDA publishes it. Check it yourself.
- If 503A: are they licensed with my state's board of pharmacy? State boards publish searchable databases.
- Which door does this specific substance go through? Monograph, component of an approved drug, or bulks list. A real answer exists. Vagueness is an answer too.
- Did anyone require a prescription and an actual clinical assessment? No prescription means no 503A pathway. That's not a shortcut — it's a different thing entirely.
A provider who can't answer 1 through 4 isn't necessarily doing something wrong. But they're asking you to take on faith something you could have verified in ten minutes.
The source
Everything above comes from one document
FDA maintains and dates the list of every substance nominated for 503A compounding and which category it sits in. It's public:
fda.gov/media/94155/downloadBulk Drug Substances Nominated for Use in Compounding Under Section 503A, updated May 14, 2026.
We mention it because it's the difference between a claim and a citation. When we tell you a compound has no pathway, that document is where we got it — and it's where you can check whether we're still right after we've stopped looking.
It's also worth knowing that widely-shared "peptide legal status" tables published by vendors frequently disagree with it. When they disagree, they disagree in one direction: toward available. You don't need to take our word for that either. Open the document.
Every molecule's status, dated, with sources → /fda-tracker
Compounded, not FDA-approved. Compounded medications — from either a 503A pharmacy or a 503B outsourcing facility — are not reviewed by the FDA for safety, effectiveness, or manufacturing the way approved drugs are. They are not the same as brand-name products, and they're only appropriate when a licensed clinician determines FDA-approved options don't fit your situation.
The useful version of all this
You don't need to become a regulatory expert. You need to know that the question has an answer, that the answer is checkable, and that a provider worth using can give it to you without flinching.
Our tracker publishes every molecule's status with the date we checked and the source we used — including the ones we can't offer you.
Questions people ask
What's the difference between a 503A and a 503B pharmacy?
A 503A is a state-licensed pharmacy that compounds for one named patient against a prescription. A 503B is an FDA-registered outsourcing facility that can produce larger batches, including for office use without a patient-specific prescription, and must follow current Good Manufacturing Practice. They're regulated by different authorities and may use different ingredients under different conditions.
Is one safer than the other?
Neither is FDA-approved, and it isn't a simple ranking. 503B facilities follow cGMP standards and are FDA-registered and inspected, which 503A pharmacies aren't. 503A compounding is patient-specific, which means a clinician is making a call about one person rather than a batch. What matters more than the category is whether the specific pharmacy is licensed, verifiable, and using a substance with a real legal pathway.
Does 503B mean FDA-approved?
No. The facility is registered with the FDA. The drug is not approved by the FDA. Those are different things, and conflating them is one of the most common misunderstandings in this category.
What does "essentially a copy" mean?
Federal law generally bars both 503A and 503B compounders from making a drug that's identical or nearly identical to a commercially available FDA-approved drug. The main exception is when the approved drug is on FDA's shortage list — because then it isn't considered commercially available.
Why did compounded GLP-1s change?
Semaglutide was on FDA's shortage list from 2022, which permitted compounding. FDA declared the shortage resolved on February 21, 2025, ending that basis, with wind-down dates of April 22, 2025 for 503A and May 22, 2025 for 503B. A legal challenge failed to secure an injunction. In April 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B clinical-need list. Narrow patient-specific 503A compounding can still apply where a documented clinical need exists — but FDA has stated that affordability is not a clinical need.
How do I verify the pharmacy filling my prescription?
Ask which pharmacy it is by name and whether it's 503A or 503B. For 503B, check FDA's published list of registered outsourcing facilities. For 503A, check your state board of pharmacy's database. Then ask which of the legal doors the specific substance goes through. A legitimate provider can answer all of it.